Fenofibrate attenuates fatty acid-induced islet β-cell dysfunction and apoptosis via inhibiting the NF-κB/MIF dependent inflammatory pathway.

[1]  D. Crispim,et al.  Current role of the NLRP3 inflammasome on obesity and insulin resistance: A systematic review. , 2017, Metabolism: clinical and experimental.

[2]  C. Apovian,et al.  Macrophage functions in lean and obese adipose tissue. , 2017, Metabolism: clinical and experimental.

[3]  R. Takayanagi,et al.  Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. , 2017, Metabolism: clinical and experimental.

[4]  F. Tinahones,et al.  Neovascular deterioration, impaired NADPH oxidase and inflammatory cytokine expression in adipose-derived multipotent cells from subjects with metabolic syndrome. , 2017, Metabolism: clinical and experimental.

[5]  L. Plank,et al.  Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. , 2017, Metabolism: clinical and experimental.

[6]  D. Tricò,et al.  Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects. , 2017, Metabolism: clinical and experimental.

[7]  B. Lamarche,et al.  C-reactive protein levels are inversely correlated with the apolipoprotein B-48-containing triglyceride-rich lipoprotein production rate in insulin resistant men. , 2017, Metabolism: clinical and experimental.

[8]  I. Rustenbeck,et al.  Metabolic amplification of insulin secretion is differentially desensitized by depolarization in the absence of exogenous fuels. , 2017, Metabolism: clinical and experimental.

[9]  J. Kullberg,et al.  Impaired adipose tissue lipid storage, but not altered lipolysis, contributes to elevated levels of NEFA in type 2 diabetes. Degree of hyperglycemia and adiposity are important factors. , 2016, Metabolism: clinical and experimental.

[10]  K. Kristiansen,et al.  Dietary fat drives whole-body insulin resistance and promotes intestinal inflammation independent of body weight gain. , 2016, Metabolism: clinical and experimental.

[11]  C. Rock,et al.  Effects of diet composition on weight loss, metabolic factors and biomarkers in a 1-year weight loss intervention in obese women examined by baseline insulin resistance status. , 2016, Metabolism: clinical and experimental.

[12]  A. D. Salbe,et al.  A human model of dietary saturated fatty acid induced insulin resistance. , 2016, Metabolism: clinical and experimental.

[13]  A. Kowluru,et al.  Hyperlipidemia and the development of diabetic retinopathy: Comparison between type 1 and type 2 animal models. , 2016, Metabolism: clinical and experimental.

[14]  Joshua Nickerson,et al.  Dietary saturated fat and monounsaturated fat have reversible effects on brain function and the secretion of pro-inflammatory cytokines in young women. , 2016, Metabolism: clinical and experimental.

[15]  I. Rustenbeck,et al.  Acute metabolic amplification of insulin secretion in mouse islets: Role of cytosolic acetyl-CoA. , 2016, Metabolism: clinical and experimental.

[16]  J. Romijn,et al.  Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans. , 2016, Metabolism: clinical and experimental.

[17]  S. Gorgani-Firuzjaee,et al.  Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. , 2016, Translational research : the journal of laboratory and clinical medicine.

[18]  W. Liu,et al.  Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice. , 2015, Atherosclerosis.

[19]  Y. Al-Abed,et al.  Novel inhibitors of macrophage migration inhibitory factor prevent cytokine-induced beta cell death. , 2014, European journal of pharmacology.

[20]  Yongde Peng,et al.  Toll‐like receptor 2/4 links to free fatty acid‐induced inflammation and β‐cell dysfunction , 2014, Journal of leukocyte biology.

[21]  M. Donath,et al.  Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. , 2013, Cell metabolism.

[22]  A. Chamson-Reig,et al.  Susceptibility to fatty acid-induced β-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β-cell lipotoxicity and islet inflammation. , 2013, Endocrinology.

[23]  T. Saksida,et al.  Macrophage migration inhibitory factor (MIF) enhances palmitic acid- and glucose-induced murine beta cell dysfunction and destruction in vitro , 2012, Growth factors.

[24]  S. Young,et al.  Localization of lipoprotein lipase and GPIHBP1 in mouse pancreas: effects of diet and leptin deficiency , 2012, BMC Physiology.

[25]  F. Nicoletti,et al.  Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine‐induced apoptosis in vitro , 2012, Clinical and experimental immunology.

[26]  W. Wahli,et al.  PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.

[27]  T. Saksida,et al.  Beta cell function: the role of macrophage migration inhibitory factor , 2012, Immunologic research.

[28]  Shuainan Liu,et al.  Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: Is that a latent disadvantage? , 2011, Journal of Translational Medicine.

[29]  G. Keating.  Fenofibrate , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[30]  A. Satoskar,et al.  Macrophage migration inhibitory factor is a therapeutic target in treatment of non‐insulin‐dependent diabetes mellitus , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  R. Kleemann,et al.  Macrophage Migration Inhibitory Factor: Critical Role in Obesity, Insulin Resistance, and Associated Comorbidities , 2010, Mediators of inflammation.

[32]  U. Boggi,et al.  The beta-cell in human type 2 diabetes. , 2010, Advances in experimental medicine and biology.

[33]  F. Pattou,et al.  Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. , 2009, Endocrinology.

[34]  I. Stojanović,et al.  Macrophage migration inhibitory factor stimulates interleukin‐17 expression and production in lymph node cells , 2009, Immunology.

[35]  F. Nicoletti,et al.  MIF in autoimmunity and novel therapeutic approaches. , 2009, Autoimmunity reviews.

[36]  C. Meisinger,et al.  Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case–Cohort Study, 1984–2002 , 2008, Diabetologia.

[37]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[38]  S. Stošić-Grujičić,et al.  Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. , 2006, International immunopharmacology.

[39]  Alberto Zambon,et al.  Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[40]  R. Holle,et al.  Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). , 2006, Diabetes care.

[41]  M. Mcdaniel,et al.  Pancreatic β-Cell Lipoprotein Lipase Independently Regulates Islet Glucose Metabolism and Normal Insulin Secretion* , 2005, Journal of Biological Chemistry.

[42]  N. Kamatani,et al.  Successful treatment with fenofibrate, a peroxisome proliferator activated receptor α ligand, for a patient with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[43]  N. Tennagels,et al.  Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1 , 2004, Diabetologia.

[44]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[45]  H. Kolb,et al.  An association of autoantibody status and serum cytokine levels in type 1 diabetes. , 2003, Diabetes.

[46]  U. Boggi,et al.  Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. , 2002, Diabetes.

[47]  S. Rhee,et al.  Saturated Fatty Acids, but Not Unsaturated Fatty Acids, Induce the Expression of Cyclooxygenase-2 Mediated through Toll-like Receptor 4* , 2001, The Journal of Biological Chemistry.

[48]  D. Porte,et al.  beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. , 2001, Diabetes.

[49]  B. Staels,et al.  Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.

[50]  M. Mcdaniel,et al.  Relative Hypoglycemia and Hyperinsulinemia in Mice with Heterozygous Lipoprotein Lipase (LPL) Deficiency , 1999, The Journal of Biological Chemistry.

[51]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[52]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[53]  J. Haefliger,et al.  Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Bucala,et al.  Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. , 1997, Critical reviews in immunology.

[55]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[56]  J. Sturis,et al.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.

[57]  J. Bernhagen,et al.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.

[58]  R. DeFronzo.  The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[59]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.